Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Concert Pharmaceuticals, Inc. (CNCE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.8800-0.0700 (-2.37%)
At close: 4:00PM EDT
2.8800 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Sign in to post a message.
  • B
    BBF
    $122M cash and capital @120m
    undervalued.
    Bullish
  • A
    Alexander
    i am long in this stock, but it was a bad idea, i think
  • A
    Andreas
    How will they be able to raise more money? The run dry before they have data.
  • L
    Leo
    All together : Hedge Funds, please make a pump, we are waiting for you. They will never come now.
  • A
    Anonymous
    Good new driving stock;
    “positive data from a Phase 2 clinical trial evaluating Fast Track-tagged CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder characterized by patchy or complete hair loss.
    The 8 mg and 12 mg dose arms both met the primary endpoint of a statistically significant proportion of patients achieving at least a 50% improvement from baseline at week 24 in an alopecia scale called SALT compared to placebo.”
  • B
    Brian
    Robert the RSI on CNCE is extreme oversold. Block below bid for over million shares to me a hedge. Positive ruling we rocket over 3 days. Negative ruling gap down which will fill over a few weeks as market realizes NCI has 5 year exclusivity.
  • C
    CT
    Shares moving today
  • j
    josh
    Mizuho Raises Price Target Concert Pharmaceuticals (CNCE) $23.00 ➝ $29.00 Buy
  • M
    MKM
    Should hopefully get a data readout on 12 mg CTP-543 cohort before long.
    They have said sometime in 3rd quarter.
    1/22/19 They announced full enrollment for a 24 week study which would be about 7/9/19 end date by my math.
    I think it took an extra month for them to present data for 4 and 8 mg dose after trial completion date. So maybe August 9th ish to report on 12 mg group. Hopefully we'll see some increased efficacy without an increase in adverse events increasing confidence for a successful phase 3.
  • F
    Frank
    Nice positive data out back to 20!
  • F
    Frank
    Nothing but a little consolidation profit taking before heading higher
  • F
    Frank
    Data due q1 2018
  • K
    Ken
    Hello, I bought 500 shares last summer.. glad something has been happening, I thought I should have put my money into bitcoins instead. Thinking about doubling down. My rationale is the general applicability of the deuteration angle and potential to generalize to many compounds, which the USPTO regulators seem to be accepting as a valid approach. Science is simple and sound. Thoughts and opinions welcome.
  • a
    adam49
    Why the need for an extra $47.1 million right now? i.e. Stock sale. As Brian said...." wait for a better price". Is there something in the "works" that requires extra capital ?
  • D
    David
    WOW.....such a quiet, lonesome, lonely message board.! Wow. I was here to ask: Is there any potential 'pending' news or results that investors are waiting for - in July or August of 2019.?? Or, is everyone not expecting anything meaningful until november / december timeframe.??
  • D
    David
    Big jump today. Who can explain it? Is there a buyout in the air?
  • a
    adam49
    if we can get a favorable ruling in court next year we should be back in the $30's ...at least. Everyone is waiting for sone positive bews for the future of the company.
  • R
    Robert
    Concert owns d-Ruxo and will bring it to market for AA. The 'no PGR' decision does not affect that as far as I can tell.
  • A
    Anonymous
    Keep the good news releases coming (alopecia Ph2 results)!!Hopefully the Ph3 mtg w/the FDA is early in 2020 & results in quick initiation of the Ph3 trial!
    Bullish
  • R
    Robert
    Biggest risk takers as of 9/29:
    1. Great Point Partners LLC - has about 7.1% of their portfolio invested in CNCE and is their #1 holding.
    2. BVF Inc. - 5.9% of their portfolio in CNCE.
    3. Lyon Street Capital, Llc - with 2.55% of their portfolio in CNCE and their #4 holding.
    4. Senzar Asset Management LLC - with 1.4% of their portfolio in CNCE.
Advertisement
Advertisement